Kornimate/medical-research-clean huggingface dataset:
effect of transcutaneous auricular nerve stimulation vs body rocking exercises on spasticity of upper limb

Conditions: Spasticity, Muscle

Summary: the primary aim of this study is to compare the effect of tans and body rocking exercises on reducing upper limb spasticity in young stroke patients( under 50). specific objectives include evaluating changes in muscle tone, motor function, pain reduction, and functional independence following each intervention.

this randomized controlled trial, rct, will involve 42 young stroke patients with upper limb spasticity randomly assigned to three groups, transcutaneous auricular nerve stimulation, body rocking exercise, or control group, usually rehabilitation. participants will receive 30-minute transcutaneous nerve stimulation session or 20 to 30-minute body rocking exercise in session 3 to 4 times a week over an 8-week period. key outcome measures include the modified ashworth scale for spasticity, the fusel-meyer assessment for motor function, the numeric rating scale for pain, and stroke impact scale for functional independence.

Eligibility criteria:
inclusion criteria: * age 35-50 years * diagnosed with stroke (ischemic or hemorrhagic) * upper limb spasticity (modified ashworth scale score ≥1) * post-stroke duration of ≥3 months * able to follow verbal and physical instructions * no contraindications to electrical stimulation or exercise therapy exclusion criteria: * severe cognitive impairment or communication disorders * history of epilepsy or uncontrolled seizures * pacemaker or implanted medical devices * severe cardiac, orthopedic, or neurological conditions * uncontrolled hypertension or diabetes * participation in another spasticity-related trial
kinesio taping effects applied with different directions and tensions

Conditions: MYOSITIS

Summary: the kinesio taping (kt ) method was developed more than thirty years ago in order to cause sensory effects through the epidermis and dermis, generating a variety of physiological effects in other systems. clinical effects are well known levels in muscle, neurological system, injuries, inflammation, edema, among other physiological effects are thus largely in the theoretical framework. objectives: the aim of this study is to evaluate the electromyographic (emg), electroencephalographic (eeg), muscle temperature and flexibility effects with the rectus femoral muscle kt application. methods: this is a pilot study with six subjects in which they were divided into two groups, a and b. group a received the application of kt from muscle origin to insertion and group b insertion to origin, with both groups taped the non-dominant limb and the dominant limb was used as control group. the first application was conducted at 0% and the second with 75 to 100% tension. evaluations were performed before the first application, immediately and 24 hours later. after this last evaluation, was withdrawn taping, evaluated without taping, reapplied 75 to 100 % of rated voltage and in sequence. the sixth last review was conducted 24 hours after this last application. before every application a specific vibration was performed on the patellar tendon in order to trigger a neurophysiological imbalance rectus femoral.


Eligibility criteria:
inclusion criteria: * individuals who have authorized the evaluation procedure and through the term informed consent; * individuals male and female of any race, duly enrolled in some college course of universidade salgado de oliveira aged between 18-50 years old; * healthy subjects without disorders of locomotion without injury history the last 6 months in the lower limbs. exclusion criteria: * they are considered unfit for research individuals who do not meet the requirements listed above ; * individuals who have higher body mass index (bmi ) to 24.99, as the concentrated presence of fat on muscles can limit the effect of bracing; * individuals with musculoskeletal disorders and referring pain. since there report that the pain and dysfunction of movement restricted range of motion and function muscular18 ; * individuals who possess too much on the thigh in which prevent proper attachment of bracing and the emg electrode , or who refuse to perform the trichotomy . * they show taping allergy ( an allergy test by putting a small bandage on the skin will be held and observed for 24 hours ) ; * patients with any contraindication how physical activity according to the guideline of the american college of sports medicine (acsm , 1995), nerve root involvement, cardiorespiratory conditions and pregnancy .

Keywords: muscle
melatonin-micronutrients for osteopenia treatment study

Conditions: Osteoporosis; Osteopenia

Summary: the investigators' long-term goal is to employ novel methods to improve bone formation and bone density in women (and men) with osteopenia or osteoporosis while also decreasing signs and symptoms of degenerative joint and disc disease that commonly accompany bone loss as well as improve quality of life (qol). these conditions generally begin silently as early as the menopause transition and progress to osteopenia and osteoporosis during the post-menopausal years in aging women. the investigators also envision this will be beneficial in aging andropausal men with these conditions. the investigators postulate that melatonin in novel combination with other natural bone-protective agents may act in a "chronosynergy" manner to prevent and correct these perturbations, reducing the risk of bone fractures, and lessening the stiffness and pain associated with bone, joint and cartilage degeneration and improving quality of life (qol). the objective here, which is the investigators' next step in pursuit of our goal, is to assess the efficacy of an alternative therapy that uses a novel combination of bone-forming agents, melatonin, strontium (citrate)/ vitamin k2 (mk7), and vitamin d3 on bone health in a postmenopausal population. melatonin is a novel alternative to current treatment(s) because it has multiple bone-protective and sleep-promoting activities within the body, and it is relatively safe so it can be used in an aging population without untoward side effects; strontium and vitamin d3 are shown to enhance bone mineralization and improve post-menopausal osteoporosis. the project goal is to identify if this combination therapy improves bone health and qol compared to women taking placebo. the investigators' central hypothesis is that combination therapy using melatonin, strontium, vitamin k2, and vitamin d3 will improve bone health and overall qol in postmenopausal women not taking this regimen by reducing osteoclast activity and increasing osteoblast activity and by improving subjective measures of stress, anxiety, depression and menopause-related symptoms.


Eligibility criteria:
inclusion criteria: * postmenopausal * must be osteopenic (t-score between -2.5 and -1) * willingness to participate in the 12-month study * willingness to undergo testing of bone turnover markers before and after the drug therapies * willingness to provide a self-assessment on quality of life throughout the program * willingness to take their treatments right before bed * willingness to not to consume alcohol with this medication exclusion criteria: * women in whom osteopenia is a result of some other known process (e.g. hyperparathyroidism, metastatic bone disease, multiple myeloma or chronic steroid use). * women on osteoporotic drugs, hypnotics, cyp1a2 inhibiting drugs, fluvoxamine * women with severe sleep apnea, severe copd and those with moderate or severe hepatic or renal impairment.

Keywords: melatonin strontium citrate osteoporosis osteopenia
a study of immunotherapy treatment in people with sarcoma

Conditions: Sarcoma

Summary: the purpose of this study is to collect information from participants' medical records to improve our knowledge about immunotherapy use and how effective it is as a treatment for people with sarcoma. immunotherapy drugs boost the immune system's ability to fight cancer by blocking proteins that act as a "brake" on the immune system. blocking these proteins is like releasing the brakes, so that the immune system can target cancer cells and destroy them. this action is sometimes described as "immune checkpoint blockade.


Eligibility criteria:
inclusion criteria: * participants must have a histologic diagnosis of sarcoma confirmed by an msk pathologist. * any prospectively identified patient being treated or to be treated with an immune checkpoint inhibitor, such as anti-pd-1, anti-pd-l1, anti-ctla-4, or anti-lag3 inhibitor, either as monotherapy or in combination with additional systemic therapy o novel immune checkpoints inhibitors that are developed after submission of this protocol will also be included) please note: there is no age requirement. patients of all ages are eligible to enroll exclusion criteria: * patient unwilling to consent to collection of historical and longitudinal clinicopathologic data in the patient medical record from baseline (the period prior to icb initiation), during, and after icb treatment

Keywords: immunotherapy immune blockade-based therapy 23-254
registry of acute ischemic stroke with large- or medium-vessel occlusion

Conditions: Acute Ischemic Stroke

Summary: this study is designed to observe the treatment options in real-world clinical practice as well as the safety and efficacy of different treatment strategies.

lomevo is a prospective, multicenter, real-world registry lasting for 10 years. a total of 50000 patients with large- or medium-vessel occlusion will be enrolled at approximately 30 centers around china.

Eligibility criteria:
inclusion criteria: * the clinical diagnosis is acute ischemic stroke with large- or medium- vessel occlusion (the criteria followed the chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018) * informed consent from the patient or surrogate exclusion criteria: * no additional exclusion criteria

Keywords: acute ischemic stroke large vessel occlusion medium vessel occlusion real-world registry
addressing kinesiophobia in post-meniscoplasty patients through progressive muscle relaxation training and acupressure

Conditions: Meniscus Tear

Summary: the objective of this clinical trial is to determine whether progressive muscle relaxation training and acupressure can reduce kinesiophobia (fear of movement) in patients recovering from meniscoplasty surgery. the study will also monitor the safety of these non-pharmacological interventions. the main questions the trial aims to answer are: does the combination of progressive muscle relaxation training and acupressure decrease kinesiophobia in post-meniscoplasty patients? what are the other benefits, if any, of these interventions in terms of pain management and functional mobility? are there any negative effects associated with these treatments? participants in the study will: receive progressive muscle relaxation training and acupressure or a placebo control treatment for a duration of 3 months. visit the clinic once every month for evaluation and follow-up treatments. keep a journal recording their fear of movement levels, pain levels, and mobility status.

this study received approval from the ethics committee of a tertiary class a hospital in lanzhou, id 202159. the research period extended from december 2021 to february 2023. subjects comprised patients who developed kinesiophobia following meniscus shaping surgery within the sports medicine department of the aforementioned hospital in lanzhou.

Eligibility criteria:
inclusion criteria: * patients confirmed with meniscal damage as per established diagnostic guidelines and subjected to meniscus sculpting surgery * individuals post-meniscus surgery exhibiting a tampa scale of kinesiophobia (tsk) score exceeding 37 points * first-time patients receiving unilateral meniscal surgery * exclusive employment of the meniscus sculpting surgical procedure * participation were entirely voluntary for all research participants exclusion criteria: * patients with compromised consciousness or communicative impairments * individuals with a history or presence of post-surgical lower limb thrombosis, resulting in activity limitation * patients enduring deformities in the hip or ankle joints * those previously engaged in analogous research endeavors
to evaluate the safety of treating autoimmune diseases with molecular hydrogen supplement

Conditions: Autoimmune Diseases

Summary: the supplementation of hydrogen molecules as an aid, adjuvant, may speed up recovering the course of the disease. the purpose of this study is to determine the safety and possible efficacy of hydrogen supplements in different formula and dose exposures for a clinical study in rheumatologic patients. patients will receive a different dosage of either hydrogen capsules, hydrogen gas or hydrogen-rich water with their conventional treatment for a month. investigators will test for any changes in haematologic, urine analysis and health status during and following the exposure period.

hydrogen supplement has been shown to have significant removing effects on free radicals. international clinical trials have shown promise that hydrogen molecules may reduce chronic inflammatory and then speed up recovering the course of the disease. the purpose of this study is to determine the safety and possible efficacy of hydrogen supplements in different formula and dose exposures for a clinical study in rheumatologic patients. study design: 27 rheumatologic patients will be recruited from the tri-service general hospital for this study. participants will be screened by doctors for their eligibility and undergo a series of tests (questionnaires and examinations). consenting participants will then be allocated into 3 groups by different dosage forms (gas, n=9; water, n=9; capsules, n=9). participants in the gas group will then undergo exposure to 2% h2 in medical air via a high flow nasal cannula for either 1 (n=3), 2 (n=3) or 4 (n=3) hours every day for one month. participants in capsule group will receive 1 (n=3), 3 (n=3) or 6 (n=3) capsules every day for one month. participants in the water group will be suggested to drink 1 l hydrogen-rich water every day for one month. participants will be examined their regular haematology, urine and health status before and after the intervention.

Eligibility criteria:
inclusion criteria: * age 20 to 80 * able to compliant with the protocol * able to return to the hospital regularly exclusion criteria: * pregnancy * expected pregnancy
phase ii dose ranging study of artesunate

Conditions: Falciparum Malaria; Uncomplicated Malaria

Summary: the purpose of this study is to compare four regimens using us fda gmp intravenous artesunate for the treatment of uncomplicated plasmodium falciparum malaria to identify the most effective treatment regimen as determined by rapidity of parasite clearance by microscopy.

to compare the efficacy and tolerability of intravenous artesunate for the initial treatment of uncomplicated plasmodium falciparum malaria at doses that bracket anticipated clinical doses (2.4 mg/kg once daily for 3 days; or 2.4 mg/kg initially, at 12 hours on day 0, and then daily on day 1 and 2) and thereby establish the safest, highly efficacious dosing regimen for use in future clinical trials.

Eligibility criteria:
inclusion criteria: 1. acute symptomatic plasmodium falciparum malaria infection as determined by malaria smear with a parasite density of ≥ 5000 asexual parasites/ml 2. age: 5-65 year old males and females. 3. written informed consent must be obtained from adults age \> 18 years. parental consent will be obtained from children and adolescents, and subject assent will also be obtained from adolescents (age 12-17 years). 4. willing to stay hospitalized for 4 days for treatment and for 3 scheduled follow-up outpatient visits at day 7, 14 and 28. exclusion criteria: 1. pregnant women (clinically or by positive urine β-hcg) and nursing mothers 2. clinical evidence of severe malaria (see appendix b) 3. mixed malaria infection on admission by malaria smear 4. a previous history of intolerance or hypersensitivity to the study drug artesunate or other artemisinin derivatives or malarone. 5. efficacious malaria drug therapy administered in the past 30 days by history (i.e. quinine, mefloquine, lumefantrine and artemisinin derivatives) 6. previous participation in this trial or participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to entry in the study. 7. laboratory evidence or a history of significant liver or renal functional abnormality. 8. anyone who has received a transfusion or any blood product within 30 days 9. unable and/or unlikely to comprehend and/or follow the protocol. 10. likelihood of requiring treatment during the study period with drugs not permitted by the study protocol.
stereotactic body radiotherapy (sbrt) for prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to evaluate the incidence of urinary and gastrointestinal acute and late side effects in patients treated with stereotactic body radiotherapy (sbrt) to the prostate. stereotactic radiation therapy is given as five treatments over a 2-3 week period. the prostate is localized and the plan is reoptimized as needed prior to each treatment.

this protocol requires radiation treatments to be performed with a stereotactic technique with the use of a 3-d coordinate system defined by implanted transponders (i.e. calypso) or use of the exactrac system and/or use cone-beam ct (cbct) with fiducial markers.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of adenocarcinoma of the prostate within 365 days of study enrollment * history/physical examination with digital rectal examination of the prostate within 8 weeks prior to study enrollment * gleason score less than or equal to 7 * clinical stage t1-t2c * psa * less than or = 15 ng/ml prior to start of therapy if gleason \< or = 6 or * less than or = 10 ng/ml prior to start of therapy if gleason = 7 * zubrod performance status 0-1 * age \> 40 exclusion criteria: * prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 5 years. (carcinoma in situ of the bladder or oral cavity is permissible) * evidence of distant metastases * regional lymph node involvement * significant urinary obstruction * estimated prostate gland \> 100 grams * previous radical surgery (prostatectomy) or cryosurgery for prostate cancer * previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy * previous hormonal therapy, such as lhrh agonists (e.g. goserelin, leuprolide), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., des), or surgical castration (bilateral orchiectomy) or planned concurrent androgen deprivation therapy * previous or concurrent cytotoxic chemotherapy for prostate cancer * prosthetic implants in the pelvic region that contain metal or conductive materials (e.g., an artificial hip). * severe, active comorbidity

Keywords: cap sbrt prostate exactrac calypso imrt radiation cancer of prostate prostatic neoplasms
implementation and evaluation of the graded repetitive arm supplementary program (grasp) for people with stroke

Conditions: Stroke

Summary: the goal of this clinical trial is to compare the effect of the graded repetitive arm supplementary program (grasp) with the usual care on upper extremity function in individuals with stroke. the main questions it aims to answer are: * compare the effectiveness of the grasp program delivered by train occupational therapists * explore the patients' and therapists' experiences of the grasp program using interviews and surveys stroke participants will receive either the grasp program or usual care for four weeks (3 sessions/week). stroke participants will be evaluated before, immediately after, and 3 months after the intervention. therapist participants will be trained for the delivery of the grasp program. interviews and surveys/questionnaires will be administered to understand patients' and therapists' perspectives on the implementation of the grasp program.


Eligibility criteria:
inclusion criteria: * 1) are aged 20 years or older, 2) stroke onset \> 3 months, 3) have upper extremity hemiparesis due to the first-ever stroke, (4) have some voluntary movement in the affected ue, including the ability to lift the affected arm to chest level and hold for 5 seconds, some ability to extend the affected wrist, and some ability to grasp and release an object such as a cup handle, and 5) are able to follow 2-step instructions. exclusion criteria: * 1) orthopedic conditions affecting the arm/hand or other neurological conditions, 2) severe pain that prevents movement in the affected arm and hand, and 3) unstable medical status.
a study comparing tazarotene cream 0.1% to tazorac® (tazarotene) cream 0.1% and both to a placebo control in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: a multi-center, double-blind, randomized, vehicle-controlled, parallel-group study comparing tazarotene cream 0.1% to tazorac® (tazarotene) cream 0.1% and both active treatments to a vehicle control in the treatment of acne vulgaris


Eligibility criteria:
inclusion criteria: * healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris. * must have a minimum of ≥ 25 non-inflammatory lesions and ≥ 20 inflammatory lesions and ≤ 2 nodulocystic lesions at baseline on the face. * must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the investigator's global assessment. exclusion criteria: * female subjects who are pregnant, nursing or planning to become pregnant during study participation. * have a history of hypersensitivity or allergy to tazarotene, retinoids and/or any of the study medication ingredients. * presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris.
dysferlinopathy protein in peripheral blood monocytes.

Conditions: Muscular Dystrophies; Limb-Girdle Muscular Dystrophy Type 2B; Miyoshi Myopathy; Distal Myopathy With Anterior Tibial Onset

Summary: the objective of the study is to answer the following important questions. deficiency of the dysferlin protein is the cause of a very rare limb-girdle muscular dystrophy (lgmd-2b) that leads to significant disability. this disease is caused by mutations in the dysferlin gene. it is a recessive inherited disease, meaning that both copies of the gene must have mutations for the disease to develop. this study aims to analyze the frequency of carriers of a mutation in the dysf gene in the caucasian population. to achieve this, the investigator analyzed the blood of 100 healthy volunteers from their local area, quantifying the dysferlin protein in peripheral blood monocytes.


Eligibility criteria:
inclusion criteria: * individuals diagnosed with dysferlinopathies. * carriers of a single mutation in the dysf gene. * participants who are willing to undergo treatment with oral vitamin d3. * subjects who can provide informed consent for participation in the study. * controls and carriers willing to participate in in vitro studies using hl60 cells, monocytes, and myotubes. exclusion criteria: * individuals with conditions or medications that could interfere with the study outcomes of dysferlin expression. * participants who are unwilling or unable to adhere to the study protocol for the duration of the study period. * pregnant or breastfeeding women. * individuals with known allergies or adverse reactions to vitamin d3 supplements. * subjects with severe concurrent illnesses that may impact the study's objectives or their ability to participate effectively.

Keywords: muscular dystrophy dysferlin limb-girdle muscular dystrophy type 2b miyoshi myopathy distal myopathy with anterior tibial onset